Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2025-05-23 00:00:00 ET · period of report 2025-05-21 · accession 0001140361-25-020376 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-23 | 2025-05-21+ | ADMA | Guiheen Lawrence P. | Dir | M - OptEx | $5.96 | +9,000 | 116.1K | +8% | +$53.6K |
| DM | 2025-05-23 | 2025-05-21+ | ADMA | Guiheen Lawrence P. | Dir | S - Sale+OE | $20.29 | -9,000 | 114.8K | -7% | -$182.6K |
| DM | 2025-05-23 | 2025-05-21+ | ADMA | Guiheen Lawrence P. | Dir | M - OptEx | $0.00 | -9,000 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-21 | M | A | 7,779 | $5.96 | 122,609 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-21 | S | D | 7,779 | $20.32 | 114,830 | D | — | — | (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.20 to $20.73. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| 3 | Common | Common Stock | 2025-05-22 | M | A | 1,221 | $5.96 | 116,051 | D | — | — | |
| 4 | Common | Common Stock | 2025-05-22 | S | D | 1,221 | $20.12 | 114,830 | D | — | — | (F2) Includes, as of the transaction date, (i) 10,889 restricted stock units granted on February 19, 2025, which vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of such vesting date; and (ii) 103,941 shares of common stock owned by the Reporting Person. The number of common shares reported includes a de minimis reduction by 10 shares from the amount previously reported due to a broker adjustment. |
| 5 | Derivative | Stock Option (right to buy) | 2025-05-21 | M | D | 7,779 | $0.00 | 1,221 | D | $5.96 · — to 2026-01-28 | 7,779 Common Stock | (F5) The Reporting Person is exercising this option due, in part, to its near-term expiration date. (F6) These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. |
| 6 | Derivative | Stock Option (right to buy) | 2025-05-22 | M | D | 1,221 | $0.00 | 0 | D | $5.96 · — to 2026-01-28 | 1,221 Common Stock | (F5) The Reporting Person is exercising this option due, in part, to its near-term expiration date. (F6) These options were granted on January 28, 2016 and vested in twenty-four equal monthly installments, becoming fully vested on January 28, 2018. |